2020
Impact of PSMA-targeted imaging with 18F-DCFPyL-PET/CT on clinical management of patients (pts) with biochemically recurrent (BCR) prostate cancer (PCa): Results from a phase III, prospective, multicenter study (CONDOR).
Morris M, Carroll P, Saperstein L, Pouliot F, Josephson D, Wong J, Pantel A, Cho S, Gage K, Piert M, Iagaru A, Pollard J, Wong V, Jensen J, Stambler N, Gorin M, Siegel B. Impact of PSMA-targeted imaging with 18F-DCFPyL-PET/CT on clinical management of patients (pts) with biochemically recurrent (BCR) prostate cancer (PCa): Results from a phase III, prospective, multicenter study (CONDOR). Journal Of Clinical Oncology 2020, 38: 5501-5501. DOI: 10.1200/jco.2020.38.15_suppl.5501.Peer-Reviewed Original ResearchPET/CTProstate cancerPrimary endpointOccult diseaseSystemic therapyLocal therapyClinical managementNovel PET imaging agentBiochemically recurrent prostate cancerDrug-related SAEsEquivocal conventional imagingMetastatic prostate cancerRecurrent prostate cancerMajority of ptsBCR prostate cancerCurrent imaging modalitiesPET imaging agentCommon AEsDefinitive therapySecondary endpointsPSA responseMulticenter studyLower PSAPCa cellsF-DCFPyL
2019
A phase III, multicenter study to assess the diagnostic performance and clinical impact of 18 F-DCFPyL PET/CT in men with suspected recurrence of prostate cancer (CONDOR).
Morris M, Pouliot F, Saperstein L, Rowe S, Gorin M, Josephson D, Wong J, Carroll P, Lin T, Stambler N, Wong V, Jensen J, Siegel B. A phase III, multicenter study to assess the diagnostic performance and clinical impact of 18 F-DCFPyL PET/CT in men with suspected recurrence of prostate cancer (CONDOR). Journal Of Clinical Oncology 2019, 37: tps5093-tps5093. DOI: 10.1200/jco.2019.37.15_suppl.tps5093.Peer-Reviewed Original ResearchF-DCFPyL PET/CTPET/CTRecurrent prostate cancerMetastatic prostate cancerProstate cancerF-DCFPyLPositron emission tomographyClinical impactDiagnostic performancePET/CT resultsEquivocal conventional imagingOpen-label studyWhole-body PET/CTProstate-specific membrane antigenYears of ageUnmet diagnostic needsEligible patientsF-fluciclovineDefinitive therapyBaseline PSAMulticenter studyDetection rateProstate adenocarcinomaPatient managementC-choline